Mounjaro tablet form: what the evidence actually shows

Step 1, Understanding what Mounjaro actually is

Mounjaro is the brand name for tirzepatide, a medicine made by Eli Lilly. It works by activating both the GIP and GLP-1 receptors in the gut, slowing gastric emptying and signalling fullness to the brain. It holds UK licences for weight management and type 2 diabetes. The tirzepatide treatment page gives a fuller picture of how the medicine fits into the GLP-1 landscape.

What tirzepatide does not have (in any market) is an approved oral tablet version, and if you have been wondering whether there is a tablet form of Mounjaro, the short answer is that every licensed dose, from the 2.5 mg starter right through to 15 mg, arrives in the same format: a pre-filled injection pen used once a week, rotating between the abdomen, thigh and upper arm. That is the only licensed route of administration described in the Summary of Product Characteristics published on the eMC, and it is the only form num prescribers can legally prescribe.

Why does this matter? Because the peptide structure of tirzepatide is broken down rapidly in the stomach. Delivering it orally would require absorption-enhancing technology similar to that developed for oral semaglutide, and no such formulation has yet reached regulatory approval in the UK. Research into oral GLP-1 and dual-agonist medicines is an active area, but active does not mean available.

Step 2, What the oral GLP-1 option that does exist looks like

If you are specifically seeking a weight-loss medicine you can swallow, there is now one option approved in the UK: Wegovy tablets (oral semaglutide), which the MHRA authorised on 11 June 2026, making the UK the first country in Europe to approve an oral GLP-1 medicine for weight management. It is a different molecule from tirzepatide. Semaglutide targets only the GLP-1 receptor; tirzepatide, as above, targets both GIP and GLP-1.

The Wegovy tablet uses an absorption enhancer called SNAC to survive the stomach environment. It is taken once daily, first thing in the morning before food or drink, and requires no refrigeration, a practical difference from Mounjaro's injection pens, which need to stay in the fridge. Trial data (OASIS 4, 307 adults, 64 weeks) showed approximately 13.6% average weight loss versus around 2.4% for placebo, rising to roughly 17% among participants who remained fully adherent throughout. If you want to explore how that compares with the injection options, the weight-loss treatment overview is a useful starting point.

Rybelsus is also oral semaglutide, but it carries a different licence (for type 2 diabetes, not weight management) so the two should not be treated as interchangeable. The Wegovy tablet is the weight-management product; Rybelsus is not.

Step 3, What clinical evidence exists for a tirzepatide tablet form

There is no published, peer-reviewed efficacy data for tirzepatide in tablet form that has been reviewed by the MHRA. The evidence base that led NICE to recommend tirzepatide in TA1026 (published December 2024) (including the SURMOUNT-1 trial, which enrolled over 2,500 adults and found average body-weight reductions around 20–21% at the 15 mg dose over 72 weeks) relates entirely to the subcutaneous injection. Those results, cited in the NICE technology appraisal for tirzepatide, cannot be assumed to predict what a tablet would achieve.

Eli Lilly has disclosed early-phase research into an oral tirzepatide formulation, and the field is moving quickly. But early-phase research and regulatory approval are separated by years of trials and independent scrutiny. A question our prescribers hear fairly regularly is whether a pill version is just around the corner; the honest answer is that no timeline is publicly confirmed, and nothing is close enough to affect prescribing decisions today. Our Mounjaro tablet page covers what is currently known about that research and what it would need to clear before anything changes. For a useful plain-English exploration of how this medicine works and what the current evidence covers, the Mounjaro information page goes into more detail.

There is also the question of how quickly Mounjaro produces an effect, worth reading if you are weighing up the injection versus waiting for a hypothetical future tablet. A medicine that may or may not reach UK approval in several years is not a realistic alternative to one that is available now.

Step 4, Where this leaves you practically

If the injection format is genuinely a barrier, oral semaglutide is the one licensed oral option. If the medicine you want is tirzepatide specifically, the injection is the only legal route. Either way, a clinician needs to assess your suitability before any prescription is issued: BMI, medical history, any contraindications, and which formulation fits your circumstances. That is not a bureaucratic hurdle, it is the part that keeps treatment safe.

Cost is sometimes part of the conversation at this point. Since Eli Lilly adjusted UK list prices in September 2025, private Mounjaro pricing has shifted; the background on that price change explains what happened and why. Understanding the cost context before you start helps set realistic expectations.

There is no need to wait for an appointment that might be weeks away. The FAQ section covers common questions about both injection and oral options, and our clinical team reviews every consultation personally. When you are ready, speak to our prescribers, no referral needed, same-day clinical review, and treatment dispatched the same day if you are approved and order before noon. The pen arrives the next working day, in plain packaging, tracked on your phone. That is the bit that tends to surprise people.